Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05111613 · ClinicalTrials.gov registry record · NA
The PEERLESS Study
A NA study, sponsored by Inari Medical.
- Completed
- Registry status
- NA
- Development phase
- 692
- Enrollment target
NCT05111613: Completed NA study, sponsored by Inari Medical.
NCT05111613 is a NA study that has completed, run by Inari Medical. The registered enrollment target is 692 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05111613, a NA study, has completed, sponsored by Inari Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 692 participants
- Enrollment target
Study Summary
A prospective, multicenter, randomized controlled trial of the FlowTriever System compared to Catheter-Directed Thrombolysis (CDT) for use in the treatment of acute pulmonary embolism. The trial includes a non-randomized cohort of subjects with an absolute contraindication to thrombolysis.
Primary Outcome
The primary endpoint is a composite constructed as a hierarchical win ratio of the following 5 components: 1. All-cause mortality, or 2. Intracranial hemorrhage (ICH), or 3. Major bleeding per ISTH definition, or 4. Clinical deterioration defined by hemodynamic or respiratory worsening, and/or escalation to a bailout therapy, or 5. ICU admission and ICU length-of-stay during the index hospitalization and following the index procedure. A win ratio larger than 1 indicates that patients who recei
Interventions
- DEVICE FlowTriever System
- DEVICE Catheter-Directed Thrombolysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 692 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2024-04-11 |
| Phase | NA |
What the finished NCT05111613 record still lists
NCT05111613 is an interventional study that assigns participants to a tested intervention. The registered 692 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 2 interventions - of which FlowTriever System is the first listed.
NCT05111613 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05111613 about?
NCT05111613 is a clinical study titled "The PEERLESS Study". A prospective, multicenter, randomized controlled trial of the FlowTriever System compared to Catheter-Directed Thrombolysis (CDT) for use in the treatment of acute pulmonary embolism. The trial includes a non-randomized cohort of subjects with an absolute contraindication to thrombolysis.
What is the current status of trial NCT05111613?
This trial is currently completed. It is a NA study. The enrollment target is 692 participants. The study started on 2022-02-14. Estimated completion is 2024-04-11.
What interventions are being tested in trial NCT05111613?
The interventions under investigation include: FlowTriever System (DEVICE), Catheter-Directed Thrombolysis (DEVICE).
Who is sponsoring clinical trial NCT05111613?
This trial is sponsored by Inari Medical, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05111613's enrollment target sits among peer trials
692 151st of 2000 higher than 1,850 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07382167 · 692 participants · Phase 3
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
- NCT07179016 · 693 participants · NA
Evaluating the Auricular Point Acupressure-Self Management Program for Chronic Musculoskeletal Pain Among Rural Populations
- NCT00532051 · 690 participants
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
- NCT05184335 · 690 participants · Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI